Nursing · Independent exam preparation
OCN® Adult Oncology Nursing: Decisions, Safety, and Supportive Care Study Guide
Practise adult oncology decisions in treatment safety, symptom assessment, emergencies, survivorship, and supportive care with 60 concepts and 20 explained questions.
By CertMedbry · Updated 28 October 2026
Learn to distinguish expected treatment effects from urgent complications, connect cancer biology to treatment choices, and individualize teaching across the adult cancer care continuum. Each concept pairs a clinical principle with a practical decision and a tempting error. The guide follows the six domains of ONCC’s linked 2026 OCN® Test Content Outline. Its 60 concepts are selective: the official outline defines the full examination scope, including topics beyond this guide. Use the questions to examine your reasoning and the flashcards to strengthen recall, then return to the outline to identify remaining study needs.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification and practice level does this guide cover?
It covers Oncology Certified Nurse, OCN®, awarded by the Oncology Nursing Certification Corporation. The examination concerns basic adult oncology nursing practice, including clinical care, administration, education, research, and consultation. ONCC separately lists AOCNP® for advanced oncology nurse practitioners, CPHON® for pediatric hematology oncology, CBCN® for breast care, TCTCN™ for transplantation and cellular therapy, and ROCN™ for radiation oncology. Their outlines should not be substituted for the OCN outline.
Oncology Certified Nurse (OCN®) | ONCC · Prepare for test | ONCC · 2026 ONCC Certification Test Registration Manual
How many questions are on the examination, and how much time is allowed?
OCN contains 165 questions: 145 scored questions and 20 unscored pretest questions. Candidates cannot identify the pretest questions. The three-hour total test session includes the tutorial and exit survey, with 15 minutes allocated to those activities. There are no scheduled breaks; the session timer continues during any break. See the manual’s OCN-specific section on page 6 and test-session instructions on pages 4 and 33. ONCC uses generic drug names.
2026 ONCC Certification Test Registration Manual · Oncology Certified Nurse (OCN®) | ONCC
How is the examination delivered, and what question format should I practise?
The examination uses computer-based testing at PSI test centers. Each question or incomplete statement has four answer options, with one correct answer. Practise selecting the single best response to the clinical information given. The registration manual describes the format on page 4 and test-center delivery on page 5.
Which blueprint and dates govern this guide?
Use the 2026 OCN Test Content Outline, which carries a 2025 copyright, together with the 2026 ONCC Certification Test Registration Manual, valid January 1, 2026. The manual identifies a basic adult oncology nursing role study completed in 2024 as the basis for the outline. Organize study by the outline’s six domains and listed subtopics.
2026 OCN® Test Content Outline · 2026 ONCC Certification Test Registration Manual
How are the official domains represented?
Official weights are Care Continuum 14%, Oncology Nursing Practice 15%, Treatment Modalities 20%, Symptom Management and Supportive Care 25%, Oncologic Emergencies 16%, and Psychosocial Dimensions of Care 10%. The 60 concepts allocate 8, 9, 12, 15, 10, and 6 concepts respectively. Both the 20-question set and the 20-card set allocate 3, 3, 4, 5, 3, and 2 items. These rounded samples cover every domain but do not exhaust its topics.
What eligibility and jurisdiction requirements are established?
The current OCN page requires an active, unencumbered RN license in the United States, its territories, or Canada; at least two years of RN experience within the preceding four years; at least 2,000 hours of adult oncology nursing practice within those four years; and at least 10 qualifying oncology education contact hours within the preceding three years. ONCC specifies acceptable education providers and limits on CME or CPE credit. All eligibility criteria must be met at application and examination.
How should this guide be combined with official preparation resources?
Use the official outline as the complete scope, ONCC’s reference list to select comprehensive study resources, and ONCC’s sample items or free practice test to become familiar with its published examples. This guide’s explanations support learning decisions; its scores do not establish readiness, an official passing standard, or a probability of passing.
This guide addresses ONCC’s Oncology Certified Nurse credential for registered nurses in basic adult oncology practice. It is independently authored educational material, not an official ONCC examination or a prediction of passing.
Outline used: 2026 OCN® Test Content Outline, copyright 2025, linked from ONCC's current examination and preparation pages; corroborated by the 2026 ONCC Certification Test Registration Manual, valid January 1, 2026. Verified for use as of October 11, 2026. The workbook label matches the official credential name; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Care Continuum14%
1.What distinguishes screening from diagnostic evaluation?
Screening looks for cancer before symptoms appear; diagnostic evaluation investigates a symptom, abnormal examination, or abnormal screening result. The distinction changes the clinical question: whether an apparently well person should be screened versus what explains a concerning finding. A screening result alone does not establish a cancer diagnosis. Candidates should recognize that a new symptom requires assessment even when a recent screening test was reassuring, because screening cannot exclude every cancer.
Apply it
A patient reports a new breast lump after a normal screening mammogram several months earlier. Explain that the lump needs diagnostic assessment; repeating the usual screening schedule does not address the current finding.
Common pitfall: Treating a recent normal screening result as permission to dismiss symptoms confuses population screening with investigation of an individual clinical problem.
2.How should risk influence a screening discussion?
Screening decisions depend on the cancer, the person’s risk, and the balance of benefit and harm. Age, family history, inherited susceptibility, and relevant exposures may alter that balance. Screening can produce false-positive results, false-negative results, and overdiagnosis, so detecting more abnormalities is not automatically better care. The useful decision is whether a supported screening approach fits this person, rather than assuming that every available test benefits every asymptomatic adult equally.
Apply it
An asymptomatic patient requests every available cancer screening test because a relative developed cancer. First clarify the relative’s diagnosis, age at diagnosis, and family pattern, then discuss appropriate risk assessment and supported screening choices.
Common pitfall: More testing can create unnecessary procedures and anxiety. Family history should inform individualized assessment, rather than trigger an indiscriminate panel of screening tests.
3.When should palliative care accompany cancer treatment?
Palliative care addresses symptoms, emotional distress, practical needs, and quality of life during serious illness. It can begin at diagnosis and continue alongside treatment intended to control or cure cancer. Referral depends on needs, not on stopping antineoplastic therapy. Persistent pain, difficult symptoms, family distress, or uncertainty about treatment goals are useful cues. The oncology team and palliative care specialists can work together rather than requiring patients to choose between symptom relief and cancer-directed treatment.
Apply it
A patient receiving potentially curative treatment has uncontrolled pain and family conflict about daily care. Recommend concurrent palliative support while the oncology team continues the planned cancer treatment and evaluates its benefits and burdens.
Common pitfall: Waiting until treatment has ended can leave substantial needs untreated. Palliative referral does not itself mean that cure is impossible or treatment must stop.
4.How does hospice differ from broader palliative care?
Palliative care is available throughout serious illness, whereas hospice focuses on quality of life when cure or disease control is no longer the goal. Both may address physical symptoms, emotional concerns, family support, and spiritual needs. The discriminating issue is the person’s goals and phase of care, not whether pain is present. Eligibility rules and covered services depend on the relevant hospice program and jurisdiction; a universal survival or coverage rule should not be assumed.
Apply it
A patient asks whether accepting symptom-management help requires enrolling in hospice. Clarify that palliative care can accompany active treatment, then explore whether the patient wants information about a separate comfort-focused hospice approach.
Common pitfall: Using palliative care and hospice interchangeably can discourage early support. Conversely, hospice discussions require attention to goals rather than symptoms alone.
5.Why should advance care planning begin before a crisis?
Advance care planning helps patients describe values, identify a person to speak for them if needed, and discuss preferences for future treatment. Beginning while the patient can participate allows clarification before urgent decisions arise. Preferences may change as illness and treatment change, so planning is an ongoing conversation. The nursing task includes eliciting what matters, communicating wishes to the team, and recognizing that documentation supports rather than replaces discussion with the patient.
Apply it
A patient starting treatment says maintaining independence matters more than prolonging hospitalization. Invite discussion of acceptable tradeoffs, identify the preferred surrogate, and help communicate those values before an acute deterioration limits participation.
Common pitfall: A signed document does not eliminate the need to reassess goals. Avoid assuming that one preference automatically determines every future treatment decision.
6.What makes a survivorship care plan actionable?
An actionable survivorship plan connects a treatment summary with follow-up responsibilities, surveillance, possible late effects, and health maintenance. It should help the patient know what was treated, which treatments were received, who coordinates each aspect of care, and which new problems to report. Follow-up needs vary with cancer and treatment history. A generic instruction to return annually is insufficient when it does not identify the relevant oncology, primary care, or rehabilitation responsibilities.
Apply it
A survivor is unsure whether oncology or primary care will monitor treatment-related problems. Review the treatment summary and follow-up plan together, identify the responsible clinicians, and clarify how new symptoms should be reported.
Common pitfall: Survivorship care is broader than recurrence testing. Omitting chronic symptoms, routine prevention, or responsibility for follow-up leaves predictable gaps after active treatment.
7.How do persistent and late treatment effects differ?
Persistent effects begin during treatment and continue afterward; late effects first become apparent months or years after treatment. Both can affect function and require evaluation. Treatment history helps identify plausible risks, but a new symptom should not automatically be attributed to previous therapy. Follow-up assessment considers treatment effects, recurrence, another malignancy, and unrelated illness as appropriate. The key distinction is timing of onset, while the practical priority is recognizing change and arranging an appropriate assessment.
Apply it
One survivor has numbness that never resolved after treatment; another develops a new functional problem years later. Record when each problem began, review prior therapies, and arrange evaluation rather than applying the same explanation automatically.
Common pitfall: Calling every post-treatment symptom a late effect obscures onset and may delay investigation. Treatment history raises possibilities; it does not establish causation.
8.How should prevention distinguish modifiable exposures from fixed risk factors?
Age and inherited susceptibility cannot be changed, but tobacco exposure, alcohol use, and ultraviolet exposure provide opportunities for risk reduction. Prevention teaching should identify an actionable behavior while preserving appropriate screening and follow-up. After cancer treatment, continued smoking can increase the chance of cancer at the same or another site. Smoking cessation support, reducing alcohol intake, sunscreen use, and avoiding tanning beds address different exposures. Risk reduction lowers risk without guaranteeing that cancer will never occur.
Apply it
A survivor with a family history of cancer believes prevention is pointless because inherited risk cannot change. Explain which risks are fixed, assess tobacco and tanning-bed use, and help select a concrete change with suitable support.
Common pitfall: Screening does not replace reducing carcinogen exposure. Avoid suggesting that healthy behaviors eliminate inherited risk or that a cancer diagnosis reflects personal blame.
Cancer Screening Overview - NCI · Follow-Up Medical Care | NCI
Oncology Nursing Practice15%
9.What distinguishes tumor grade from cancer stage?
Tumor grade describes how abnormal cancer cells and tissue look microscopically and can indicate how aggressively a tumor may behave. Stage describes the extent of cancer in the body. They answer different questions and may use cancer-specific classification systems. A high-grade tumor can still be localized, while a lower-grade tumor may have spread. Interpret the pathology and staging information together rather than treating either measure as a complete description of prognosis or treatment needs.
Apply it
A patient reads that a tumor is high grade and concludes it has spread throughout the body. Explain that grade describes microscopic features; the team uses separate staging information to determine the extent of disease.
Common pitfall: High grade does not mean advanced stage. Avoid translating one classification into the other or assuming that all cancers use identical grading systems.
10.Why does performance status matter beyond diagnosis?
Performance status describes how disease affects a person’s ability to perform ordinary activities and care for themselves. It adds functional information that a diagnosis or stage cannot provide alone. Changes in walking, work, self-care, or time spent resting can affect treatment discussions and supportive needs. Document observable abilities rather than relying on a vague statement that the patient looks well. Use the specified scale consistently, because different performance-status systems are not interchangeable numerical labels.
Apply it
A patient with unchanged imaging now needs help bathing and spends much of the day resting. Communicate the functional decline explicitly so treatment planning includes current capability, rather than relying only on stable disease measurements.
Common pitfall: Stable imaging does not prove stable function. Assigning an unsupported numerical score is less useful than accurately describing the activities the patient can perform.
11.How does tumor profiling differ from inherited-risk testing?
Tumor biomarker testing examines features of cancer that may help select treatment. Inherited-risk testing evaluates changes that may be present throughout the body and passed through families. A tumor result can raise suspicion of an inherited change, but tumor testing alone may not establish that the finding is germline. The important decision is whether additional genetic evaluation and confirmatory testing are indicated before making conclusions about relatives or lifelong inherited cancer risk.
Apply it
A patient’s tumor report identifies a variant associated with hereditary cancer. Explain that the result may guide treatment, while a separate genetic evaluation may be needed before concluding that the patient’s children inherited increased risk.
Common pitfall: A tumor mutation is not automatically an inherited mutation. Premature family conclusions can create unnecessary alarm or incorrectly reassure relatives who need formal assessment.
12.Why does head and neck cancer assessment require attention to oral and swallowing function?
Tumor location and treatment field determine which functions are threatened. Head and neck treatment can affect salivary glands, oral tissues, jaw movement, and swallowing. Baseline assessment should document dentition, mouth opening, pain, saliva, swallowing, and intake so subsequent changes can be recognized. Dental disease should be evaluated before treatment when feasible. Dry mouth and restricted jaw opening may persist after radiation, while invasive dental procedures later require attention to the risk of osteoradionecrosis.
Apply it
Before head and neck radiation, a patient reports painful teeth and limited mouth opening but stable weight. Communicate these findings for dental and functional assessment before treatment; weight alone does not capture the threatened functions.
Common pitfall: A head and neck diagnosis requires more than a generic symptom checklist. Waiting until the patient cannot eat misses opportunities to address dental disease and establish functional baselines.
Oral Complications (PDQ®) - NCI · Mouth and Throat Problems: Cancer Treatment Side Effects | NCI
13.How can gastrointestinal tumor location help explain a symptom pattern?
Different gastrointestinal sites threaten different steps in eating and digestion. Esophageal disease can impair swallowing; stomach involvement or gastric surgery can produce early satiety; pancreatic and small-intestinal disease may contribute to malabsorption; large-intestinal tumors may produce constipation or obstruction. These associations guide focused history and examination without establishing a diagnosis from one symptom. Ask whether the problem involves swallowing, meal tolerance, digestion, or stool passage, then connect the findings with the known site and treatment history.
Apply it
A patient with pancreatic cancer reports diarrhea and weight loss despite trying to eat more. Assess stool and intake changes and communicate concern about impaired digestion or absorption instead of assuming inadequate effort or appetite alone.
Common pitfall: The label gastrointestinal cancer does not predict one uniform nutritional problem. Increasing calories alone may fail when swallowing, passage, or absorption is impaired.
14.What makes clinical-trial consent an ongoing process?
Informed consent involves understandable discussion of a trial’s purpose, procedures, foreseeable risks, possible benefits, and alternatives. A signature records agreement but does not end the process. Participants may ask questions and should receive important new information that could affect willingness to continue. Participation is voluntary, including the ability to withdraw. Nursing assessment should look for understanding and freedom from pressure, especially when a patient believes that enrollment guarantees benefit or is required to receive care.
Apply it
A participant learns of a newly identified trial risk and asks whether the original consent prevents withdrawal. Explain that participation remains voluntary and help arrange discussion of the new information and available care options.
Common pitfall: A signed form does not establish continuing understanding. Avoid treating enrollment as an irrevocable commitment or suggesting that research participation guarantees therapeutic benefit.
15.Why are participants randomized in some clinical trials?
Randomization assigns participants to study groups by chance to reduce allocation bias and make treatment comparisons more reliable. It does not mean that clinicians select the group they believe will work best for each individual. Random assignment also does not establish that an experimental treatment is superior; the comparison exists because an important question remains unanswered. Candidates should distinguish the scientific purpose of balanced comparison from the separate consent requirement that patients understand the available study groups.
Apply it
A patient requests that the nurse ask the investigator to place them in the experimental group of a randomized trial. Explain the chance-based assignment process and help the patient discuss whether that uncertainty fits their preferences.
Common pitfall: Describing randomization as personalized treatment selection misrepresents the study. Experimental treatment can be better, similar, or worse than the comparison being studied.
16.How do blood-cell functions guide assessment during marrow suppression?
Blood-forming stem cells produce white blood cells, red blood cells, and platelets. These support infection defense, oxygen transport, and clot formation respectively. Marrow suppression therefore creates several distinct assessment priorities: infection symptoms, reduced activity tolerance, and bleeding. Review the affected cell lines and their trends rather than treating the complete blood count as one measure of wellness. Functional recovery and immune recovery also differ; after transplantation, improving counts do not mean that all immune defenses have recovered.
Apply it
A transplant recipient reports improved energy as counts recover and assumes infection precautions can stop. Explain the separate roles of red-cell recovery and immune recovery, and reinforce the transplant team’s ongoing infection-prevention plan.
Common pitfall: Improvement in one cell line does not establish recovery of every marrow function. A normal-looking patient or improving energy cannot substitute for the relevant counts and clinical assessment.
Stem Cell Transplants in Cancer Treatment | NCI · Infection and Neutropenia during Cancer Treatment | NCI · Bleeding and Bruising and Cancer Treatment | NCI
17.Why are hazardous-drug exposure controls layered?
Use a biological safety cabinet when preparing antineoplastic drugs to contain hazardous material at the work area. Supplementary closed-system transfer devices, where applicable, reduce escape of liquid or aerosol during transfers; they do not replace the cabinet. Chemotherapy gloves protect hands, while a nonabsorbent, closed-front gown with tight-fitting cuffs protects skin and clothing from contamination. These controls serve different functions and must accompany safe work practices and training. A small spill still requires the designated hazardous-drug spill procedure.
Apply it
A nurse approaches an antineoplastic spill wearing ordinary examination gloves. Stop cleanup, restrict access, and activate the designated spill procedure so trained staff use the specified spill kit and protective equipment.
Common pitfall: Routine examination gloves, an absorbent open-front gown, or a transfer device alone do not provide the combined containment and personal barriers required for hazardous-drug work.
Treatment Modalities20%
18.How does conventional chemotherapy produce both antitumor effects and normal-tissue injury?
Conventional cytotoxic chemotherapy kills or suppresses fast-growing cells, including cancer cells and some normal cells. Injury to normal oral and intestinal tissues helps explain mucositis and gastrointestinal toxicity; marrow injury helps explain impaired blood-cell production. Systemic administration can reach disease beyond one treatment field, whereas surgery and most external beam radiation act locally. This relationship between treatment reach and normal-tissue injury explains why symptom assessment and blood-count monitoring accompany treatment. See NCI’s chemotherapy overview: https://www.cancer.gov/about-cancer/treatment/types/chemotherapy.
Apply it
A patient asks why chemotherapy causes mouth sores when the tumor is elsewhere. Explain that systemic treatment also reaches susceptible normal tissues, then connect oral care and blood-count monitoring with those effects.
Common pitfall: Normal-tissue toxicity does not prove that a tumor is responding. Likewise, limited adverse effects do not establish treatment failure; response requires its own assessment.
Nutrition in Cancer Care (PDQ®) - NCI · Oral Complications (PDQ®) - NCI · Stem Cell Transplants in Cancer Treatment | NCI
19.Why is a patient not radioactive after external beam treatment?
External beam radiation delivers radiation from a machine outside the body. The beam is present during treatment; a radioactive source is not left inside the patient. After the session, ordinary contact does not expose family members to radiation from that treatment. This differs from therapies that place radioactive material in or near the body. Identify the actual modality before teaching precautions, because unnecessary isolation can create distress and misunderstandings about otherwise safe family contact.
Apply it
After external beam treatment, a patient plans to avoid grandchildren because they fear emitting radiation. Explain that this treatment leaves no radioactive source in the body and does not require separation from family afterward.
Common pitfall: Do not transfer implanted-source precautions to external beam therapy. The treatment name and source location determine radiation-safety teaching, not the cancer diagnosis.
20.When do temporary brachytherapy precautions end?
Brachytherapy places a radioactive source in or near the treatment area. During temporary treatment, precautions limit other people’s exposure while the source remains in place. Once the temporary radioactive source has been removed, it no longer makes the patient radioactive. The important distinction is removal of the source rather than removal of every catheter or applicator. Permanent implants follow different instructions, so discharge teaching must identify whether the radioactive material is temporary or remains in the body.
Apply it
A patient’s temporary brachytherapy source has been removed, but a nonradioactive applicator remains briefly. Clarify source-removal status with the team and explain why continuing implanted-source visitor restrictions is not justified solely by the remaining applicator.
Common pitfall: An applicator is not necessarily radioactive. Conversely, completion of a treatment session does not prove source removal when a permanent implant was used.
21.What is the purpose of an autologous stem cell transplant?
An autologous transplant returns the patient’s own previously collected blood-forming stem cells after intensive treatment. Its principal role is to restore blood-cell production damaged by treatment, allowing recovery of marrow function. Because the cells come from the patient, classic donor-derived graft-versus-host disease is not the defining risk. Infection and other treatment-related complications remain important during recovery. Distinguish the source of the cells from the intensity or toxicity of the preceding cancer treatment.
Apply it
A patient whose own stored cells will be returned asks whether a sibling must be matched. Explain that this is an autologous transplant and review the recovery support needed while blood-cell production is re-established.
Common pitfall: Using the patient’s own cells does not make transplantation risk-free. It changes the graft source and immune complications, not the need for close monitoring.
22.Why can allogeneic transplantation cause graft-versus-host disease?
Allogeneic transplantation uses blood-forming stem cells from a donor. Donor immune cells can attack remaining cancer cells, but they may also recognize the recipient’s healthy tissues as foreign, producing graft-versus-host disease. This direction of immune attack distinguishes it from the recipient rejecting a graft. Skin, gastrointestinal, and liver problems can be relevant manifestations. New symptoms require transplant-team assessment because infection, treatment toxicity, and graft-versus-host disease may overlap rather than being distinguishable from one symptom alone.
Apply it
An allogeneic transplant recipient develops a new rash and persistent diarrhea. Report the findings promptly for transplant-team evaluation, recognizing possible graft-versus-host disease while preserving assessment for infection and other competing causes of the symptoms.
Common pitfall: Graft-versus-host disease means donor immune cells attack recipient tissues. Do not describe it as the recipient’s immune system rejecting the donor cells.
23.How do tumor removal, debulking, and symptom-relieving surgery differ?
Surgery can remove an entire localized solid tumor, remove part of a tumor when complete removal would damage important structures, or relieve symptoms such as pain or pressure. Debulking leaves residual tumor deliberately and may help other treatments work better. Symptom-relieving surgery is judged by its intended comfort or functional benefit rather than an assumption of cure. Nursing preparation should clarify the operative goal, expected anatomical changes, pain plan, wound care, and infection or bleeding warning signs.
Apply it
A patient scheduled for debulking believes any tumor remaining afterward means the operation failed. Explain the planned partial removal and its role in the overall treatment strategy, then review expected recovery and postoperative reporting instructions.
Common pitfall: Incomplete removal does not automatically mean an unsuccessful procedure. Conversely, symptom relief or removal of a visible mass does not establish eradication of all cancer.
24.How does endocrine therapy control hormone-sensitive cancer?
Endocrine therapy slows or stops cancers that use hormones to grow by reducing hormone production or interfering with hormone action. Its usefulness depends on the cancer’s biology; the same mechanism does not apply to every tumor. It may be used at different points in a treatment plan and is not equivalent to hormone replacement. Candidates should connect the treatment mechanism with the relevant hormone dependence and recognize that a tablet can be an active cancer treatment with clinically important adverse effects.
Apply it
A patient assumes an endocrine tablet replaces hormones lost during treatment. Explain that the cancer therapy is intended to reduce a growth signal or block its action, and review the prescribed purpose before addressing adherence concerns.
Common pitfall: Endocrine therapy is not universally effective across cancers. Avoid confusing hormone blockade with hormone supplementation or assuming oral administration means minimal toxicity.
25.How do localized tissue-destruction procedures differ from systemic treatment?
Localized procedures destroy tissue in a selected area. Cryosurgery uses extreme cold; radiofrequency ablation generates heat; photodynamic therapy activates a drug with light to kill nearby abnormal cells. The mechanism and treated location determine the intended effect and relevant tissue assessment. These approaches do not imply that distant disease receives equivalent treatment. Clarify the target, procedural goal, and expected local effects before teaching recovery or interpreting response.
Apply it
A patient scheduled for ablation of one tumor assumes the procedure will treat every cancer deposit. Explain its local target and ask the team to clarify how other disease sites are addressed in the overall plan.
Common pitfall: A procedure can destroy a tumor without removing it surgically. Local control also does not establish control of disease outside the treated area.
26.What distinguishes CAR T-cell therapy from a conventional drug infusion?
CAR T-cell therapy uses a patient’s T cells that are collected and modified to recognize a target on cancer cells, then expanded and returned to the patient. The infused cells can become activated and multiply, creating antitumor activity and distinctive toxicities. This cellular process differs from simply administering a fixed amount of a conventional drug. Teaching should connect the individualized manufacturing process and immune activation with the need for specialized preparation, monitoring, and rapid reporting of concerning symptoms.
Apply it
A patient asks why their treatment requires cell collection before the infusion appointment. Explain the modification and expansion steps, then connect the returned cells’ immune activity with the monitoring planned after treatment.
Common pitfall: CAR T-cell therapy is not a standard chemotherapy dose with a different name. Living-cell activity helps explain why its monitoring and toxicity pattern differ.
27.How should an oral therapy adherence assessment uncover barriers?
Oral antineoplastic treatment shifts much of daily administration to the patient or caregiver. Adherence assessment should explore understanding, schedule complexity, adverse effects, cost, access, and practical routines rather than simply asking whether every dose was taken. A nonjudgmental discussion makes hidden problems more likely to emerge. The appropriate response depends on the barrier: reminders cannot solve unaffordable medication, and financial assistance cannot correct a misunderstood schedule. Assess the reason before selecting an intervention.
Apply it
A patient reports taking tablets only on days they feel well. Ask what symptoms or beliefs drive that pattern, compare their routine with the prescribed schedule, and arrange symptom-management and teaching support before choosing a reminder tool.
Common pitfall: Labeling the patient noncompliant can conceal solvable barriers. A refill record or a yes-or-no answer does not fully establish correct daily administration.
Adherence to Oral Agents for Cancer | Oncology Nursing Society · Financial Toxicity and Cancer Treatment (PDQ®)–Patient Version | NCI
28.What should patients do after a missed oral cancer dose?
A missed-dose plan must match the specific medication and prescribed regimen. Patients should have clear written instructions and a contact route before treatment begins. Taking extra tablets to compensate can increase toxicity and should not be improvised. Vomiting after a dose also does not justify an automatic replacement because the absorbed amount is uncertain. The central teaching is to use the medication-specific plan, report recurring problems, and avoid independently doubling, replacing, or changing scheduled doses.
Apply it
A patient cannot remember whether an oral antineoplastic dose was taken and plans to take another. Have the patient use the written medication instructions and contact the treatment team rather than guessing or adding an unscheduled dose.
Common pitfall: There is no universal catch-up rule for oral cancer drugs. Advice appropriate for one agent or schedule may be unsafe for another.
Adherence to Oral Agents for Cancer | Oncology Nursing Society · OralChemoSafetyatHome.pdf
29.Why does an oral antineoplastic still require exposure precautions?
The oral route does not remove a drug’s hazardous properties. Handling tablets, damaged capsules, contaminated packaging, or related waste may create exposure opportunities. Patients and caregivers need instructions appropriate to the actual product and task, including whether tablets must remain intact and how medication should be stored and handled. The discriminating issue is the drug’s hazard, rather than whether it is administered at home. Unapproved crushing or opening can change exposure and administration safety.
Apply it
A caregiver wants to crush an oral cancer tablet to make swallowing easier. Pause that plan and obtain product-specific administration guidance, including an appropriate alternative if needed, before altering the dosage form or exposing the caregiver.
Common pitfall: Home treatment does not mean ordinary household handling is sufficient. Do not assume tablets can be crushed or capsules opened without checking the specific product.
Chemical Hazards Risk Factors | CDC/NIOSH · Adherence to Oral Agents for Cancer | Oncology Nursing Society · OralChemoSafetyatHome.pdf
Symptom Management and Supportive Care25%
30.How should pain assessment distinguish mechanism and impact?
Cancer pain assessment includes location, intensity, timing, quality, triggers, relieving factors, and effect on function. Aching or movement-related pain can suggest tissue injury, while burning, shooting, or electric sensations can suggest a neuropathic component. These descriptions guide further assessment rather than proving a diagnosis. A numerical score alone cannot show whether the patient can sleep, walk, or complete care. The useful decision combines symptom characteristics with functional goals and the response to current treatment.
Apply it
A patient reports moderate pain but cannot sleep because of burning sensations in the feet. Document the quality and sleep disruption, review the existing regimen, and communicate the possible neuropathic component rather than recording intensity alone.
Common pitfall: Similar pain scores can represent different mechanisms and burdens. Do not select treatment solely from the number or assume all cancer pain is identical.
31.How is breakthrough pain different from uncontrolled baseline pain?
Breakthrough pain is a transient flare occurring despite otherwise controlled background pain. Prescribed immediate-release rescue medication can address an episode more appropriately than an unscheduled extra long-acting dose. Repeated flares, end-of-dose pain, or persistent pain between episodes require reassessment of the overall regimen and cause. The discriminating cues are the baseline level, timing, trigger, and rescue response. Nursing assessment should establish the pattern before assuming that every increase in pain represents the same management problem.
Apply it
A patient with comfortable baseline pain develops a brief severe flare during dressing changes. Review the prescribed rescue plan and episode timing, then report frequent or poorly relieved flares for reassessment of the broader pain strategy.
Common pitfall: Long-acting medication is not an interchangeable rescue dose. Persistent uncontrolled pain also should not be repeatedly relabeled as isolated breakthrough episodes.
32.Why should constipation prevention accompany opioid treatment?
Opioids can slow intestinal movement and cause constipation even when they relieve pain effectively. Prevention and monitoring should begin with treatment rather than waiting for prolonged discomfort. Review the patient’s usual bowel pattern, current medicines, fluid and food intake, activity, and prescribed bowel regimen. Effective pain control and bowel care can proceed together. New severe abdominal pain, vomiting, or a marked change from baseline requires assessment rather than automatic escalation of a routine constipation plan.
Apply it
A patient starting regular opioid analgesia says bowel care can wait until constipation becomes troublesome. Explain the predictable adverse effect, establish the baseline bowel pattern, and review the prescribed prevention plan and symptoms requiring contact.
Common pitfall: Stopping needed analgesia is not the first solution to predictable constipation. Conversely, escalating laxatives without assessing concerning abdominal symptoms can miss another problem.
Pain and Cancer Treatment | NCI · Constipation and Cancer | NCI
33.How can oral care reduce mucositis-related distress?
Inflamed oral tissues make eating, drinking, and routine mouth care painful. Gentle cleaning, a soft toothbrush, and recommended bland rinses help maintain oral hygiene without adding avoidable irritation. Food temperature, texture, and acidity also affect comfort. Assess ulcers, pain, swallowing difficulty, and intake because worsening symptoms can compromise nutrition and hydration. The decision is not merely which rinse to use, but whether the patient can maintain adequate intake and needs additional treatment or evaluation.
Apply it
A patient with mouth soreness has stopped brushing and is drinking acidic juice because it feels refreshing initially. Teach gentle oral cleaning and nonirritating alternatives, then assess actual intake and whether pain is limiting swallowing.
Common pitfall: Harsh or alcohol-containing rinses may worsen irritation. Avoiding oral care entirely can create additional problems rather than protecting already sensitive mouth tissues.
Mouth and Throat Problems: Cancer Treatment Side Effects | NCI
34.Which diarrhea findings change the urgency of assessment?
Diarrhea assessment compares current stool frequency and consistency with the patient’s baseline and considers timing, treatment exposure, medicines, abdominal symptoms, and hydration. Blood, fever, significant pain, dizziness, or inability to maintain fluids increases concern. The same number of stools may represent different severity for different patients. Treatment-associated diarrhea has several possible causes, including infection and immune-mediated inflammation, so a generic antidiarrheal plan should not replace assessment when warning signs or relevant treatment exposures are present.
Apply it
A patient reports several watery stools, dizziness on standing, and reduced drinking. Establish the change from baseline and current treatment exposure, then arrange timely assessment of hydration and cause rather than offering dietary advice alone.
Common pitfall: Counting stools without context can underestimate severity. Do not assume that every episode during cancer treatment is a harmless, expected medication effect.
35.Why can nausea occur before treatment begins?
Anticipatory nausea can develop when previous treatment-related nausea becomes associated with sights, smells, places, or other cues. The symptoms can therefore begin before the next treatment is administered. This learned association is clinically meaningful rather than evidence that the patient is inventing symptoms. Good control of earlier nausea helps reduce the opportunity for conditioning. Once established, management may include behavioral approaches alongside the prescribed nausea plan, rather than relying only on medication after vomiting has started.
Apply it
A patient becomes nauseated in the clinic parking area before receiving treatment. Ask about prior episodes and recognizable triggers, then connect the patient with the team’s anticipatory-nausea strategy and improved control of treatment-related symptoms.
Common pitfall: Symptoms before drug administration do not exclude a treatment-related problem. Dismissing anticipatory nausea as merely psychological undermines assessment and effective symptom support.
36.When does vomiting require assessment beyond another antiemetic?
Persistent vomiting can interfere with fluids, nutrition, and absorption of essential medicines. Assessment should establish frequency, timing, prescribed antiemetic use, ability to retain liquids, urine changes, and associated symptoms. A patient who cannot maintain intake may need evaluation for dehydration and the underlying cause rather than simply another home dose. Treatment-related nausea is common, but other causes remain possible. The discriminating issue is the effect on hydration and function, not merely whether vomiting was an expected adverse effect.
Apply it
A patient has vomited repeatedly and cannot retain fluids or prescribed tablets. Arrange prompt assessment of hydration and symptom control, documenting what was taken and retained rather than advising repeated oral doses without further evaluation.
Common pitfall: Expected toxicity can still become dangerous. Do not assume an oral medicine will work when it cannot be retained or absorbed reliably.
37.How should nutrition assessment respond to weight loss?
Nutrition assessment combines weight trend with food intake, symptoms, swallowing ability, treatment effects, and functional change. A single weight or body size does not establish adequate nutrition. Appetite loss, early fullness, mouth pain, nausea, and other problems can reduce intake through different mechanisms, requiring different interventions. Dietitian support helps individualize strategies rather than relying on a generic instruction to eat more. The important cue is a declining ability to meet nutritional needs, including in someone who remains above their previous target weight.
Apply it
A patient with a larger body size has lost weight unintentionally and eats very little because of mouth pain. Recognize nutritional risk, address the intake-limiting symptom, and arrange individualized dietitian assessment rather than praising the weight loss.
Common pitfall: Higher body weight does not rule out malnutrition. Advice to increase calories will be ineffective if the symptom preventing eating remains untreated.
38.Why should fatigue management combine assessment and activity?
Cancer-related fatigue can be persistent and disproportionate to recent activity. Assessment explores severity, daily impact, sleep, pain, medicines, nutrition, emotional distress, and other potentially contributing problems. Individualized activity balanced with planned rest can support function; prolonged inactivity is not automatically restorative. The appropriate plan depends on current ability and safety. A new or substantial change deserves evaluation rather than being dismissed as inevitable. Follow-up should ask whether the strategy improves meaningful activities, not simply whether more hours were spent resting.
Apply it
A patient responds to fatigue by remaining in bed all day and reports worsening difficulty with routine tasks. Assess contributing symptoms and current safety, then help plan tolerable activity periods with rest and reassessment.
Common pitfall: Prescribing complete rest can worsen deconditioning. Conversely, urging exercise without assessing new symptoms or functional limits overlooks potentially reversible or urgent contributors.
39.How does peripheral neuropathy change safety teaching?
Peripheral neuropathy may cause numbness, tingling, pain, weakness, or difficulty sensing position and temperature. Sensory loss can produce injury without a strong warning sensation, while balance changes increase fall risk. Assessment should connect symptoms with walking, footwear, hand tasks, and household hazards. Practical measures include safer walking environments and caution with hot surfaces or water. Early reporting is important because increasing functional difficulty may affect treatment decisions and supportive interventions, even when pain itself is mild.
Apply it
A patient denies severe pain but has numb soles and recently tripped on a rug. Treat the sensory and balance changes as clinically important, review fall hazards and footwear, and communicate the functional change to the team.
Common pitfall: Absence of pain does not mean absence of neuropathy risk. Do not use painful symptoms as the only trigger for safety assessment.
Nerve Problems (Peripheral Neuropathy) and Cancer Treatment | NCI
40.Which early symptoms suggest lymphedema?
Damage to lymphatic drainage can allow fluid to accumulate in affected tissues. Early symptoms may include heaviness, tightness, subtle swelling, or clothing and jewelry fitting differently before obvious enlargement develops. Prompt assessment matters because early management can help limit progression and functional burden. A history of lymph node treatment increases suspicion but does not explain every swollen limb. Sudden swelling, redness, pain, or systemic symptoms also requires evaluation for other causes rather than automatic attribution to chronic lymphedema.
Apply it
After lymph node treatment, a patient notices a sleeve feels tighter and the arm feels heavy despite little visible swelling. Arrange assessment for early lymphedema and document the onset and associated symptoms rather than waiting for marked enlargement.
Common pitfall: Visible swelling is not required for early concern. Avoid diagnosing every new limb change as lymphedema without considering infection or other explanations.
41.How should thrombocytopenia alter bleeding precautions?
Platelets support clot formation, so treatment-related thrombocytopenia can increase bruising and bleeding. Teaching should reduce avoidable trauma and identify bleeding that needs prompt reporting, including persistent bleeding, blood in urine or stool, and new concerning neurological symptoms. Review over-the-counter medicines because some can worsen bleeding risk. Precautions should fit the person’s clinical situation rather than an invented universal activity rule. The useful decision connects laboratory risk with observed bleeding, exposure to injury, and medicines that affect hemostasis.
Apply it
A patient with low platelets reports taking an over-the-counter pain medicine and having recurrent nosebleeds. Review the product, assess the bleeding pattern, and notify the team rather than assuming that minor visible bleeding is always harmless.
Common pitfall: Small bruises and serious bleeding are not interchangeable. Avoid reassuring solely from appearance or recommending nonprescription medicines without checking their effects on bleeding.
42.What catheter changes should trigger infection assessment?
A vascular access device can provide an entry route for infection. Redness, warmth, swelling, tenderness, or drainage near the site should be reported, and fever or chills can indicate a broader problem even when the insertion site appears normal. Assess both local findings and the patient’s overall condition. The practical distinction is between inspecting the dressing alone and evaluating the person with the device. Absence of visible drainage does not rule out a clinically important catheter-related infection.
Apply it
A patient with a central catheter reports chills but says the dressing looks clean. Assess temperature and overall symptoms, ask about site changes, and arrange prompt clinical review rather than using dressing appearance as reassurance.
Common pitfall: A normal-looking insertion site cannot exclude bloodstream infection. Do not wait for pus, marked redness, or a damaged dressing before responding to systemic symptoms.
43.How should constipation assessment identify a change from baseline?
Constipation includes hard stools, difficult passage, straining, or a meaningful reduction from the person’s normal pattern; frequency alone is incomplete. Review opioids and other medicines, intake, activity, and the prescribed bowel plan. Ask about abdominal pain, distension, nausea, vomiting, and ability to pass gas because these may change the urgency of evaluation. The decision is whether this is uncomplicated constipation suitable for the existing plan or a presentation requiring assessment before more bowel treatment is added.
Apply it
A patient who usually passes stool daily now reports several days without a bowel movement plus increasing abdominal pain and vomiting. Arrange assessment rather than advising an automatic increase in the usual home laxative regimen.
Common pitfall: A familiar history of constipation does not explain every episode. New associated symptoms can make the usual self-management advice inappropriate until assessed.
44.How can nonpharmacologic methods complement cancer pain treatment?
Relaxation, guided imagery, distraction, and other appropriate supportive approaches can reduce pain-related distress and improve coping alongside prescribed analgesia. Their value is assessed through comfort and function rather than an assumption that one method works for everyone. The patient’s preferences and clinical condition guide selection. These approaches do not remove the need to investigate a new pain pattern or provide indicated medication. Integrating them works best when the patient has a clear analgesic plan and realistic expectations.
Apply it
A patient finds guided breathing helpful during painful care but still has significant pain. Support the preferred technique while reviewing the prescribed analgesic plan and whether the procedure-related pain requires additional assessment or medication timing changes.
Common pitfall: Improved coping does not prove the pain is psychological or adequately treated. Complementary methods should not become a reason to withhold necessary analgesia.
Oncologic Emergencies16%
45.What metabolic pattern suggests tumor lysis syndrome?
Rapid destruction of cancer cells releases intracellular potassium and phosphate and increases uric acid production from nucleic acids. The resulting pattern includes hyperkalemia, hyperphosphatemia, hyperuricemia, and secondary hypocalcemia. Acute kidney injury and cardiac or neurological complications can follow. The combination of susceptible disease, treatment timing, and changing laboratory values is more informative than one abnormal result alone. Recognizing the mechanism explains why renal function, fluid balance, electrolytes, and cardiac risk require coordinated surveillance.
Apply it
After treatment for a high-burden hematologic malignancy, a patient develops rising potassium, phosphate, uric acid, and creatinine with falling calcium. Recognize the coordinated pattern as possible tumor lysis and escalate urgently for assessment and management.
Common pitfall: Do not expect calcium to rise with the other released substances. A normal initial creatinine also does not eliminate the risk of subsequent kidney injury.
46.Why must tumor lysis prevention include agent-specific safety checks?
Large burdens of rapidly proliferating, treatment-sensitive disease and impaired renal function increase tumor lysis risk. Plan hydration, laboratory surveillance, and prescribed uric-acid management before therapy. Allopurinol reduces formation of new uric acid; rasburicase oxidizes existing uric acid to more soluble allantoin. That oxidation generates hydrogen peroxide, creating oxidative hemolysis risk in G6PD deficiency. Rasburicase must not be administered to patients with G6PD deficiency. Verify required screening before treatment; prescribing information specifically requires screening patients at higher risk.
Apply it
A high-risk patient has a rasburicase order and documented G6PD deficiency. Withhold rasburicase, notify the prescriber immediately, and arrange an alternative tumor lysis plan; close monitoring does not make administration acceptable.
Common pitfall: G6PD deficiency is a contraindication, not merely a reason for additional observation. Allopurinol and rasburicase also have different actions and cannot be substituted without revising the treatment plan.
47.Why is fever during neutropenia an emergency, and what nursing response is required?
Reduced neutrophil defenses allow infection to progress rapidly, sometimes with few local inflammatory findings. Patients receiving cancer treatment should report a temperature of 38°C or higher immediately; they should not wait for a blood count or take an antipyretic before contacting the team. This contact instruction differs from diagnostic criteria. eviQ defines neutropenic fever as temperature at least 38°C with an absolute neutrophil count below 0.5 × 10^9/L, or below 1.0 × 10^9/L with a predicted fall below 0.5 × 10^9/L within 48 hours. Assess immediately for hypotension, altered mentation, respiratory compromise, reduced urine output, and other organ dysfunction. Obtain blood cultures promptly, ideally before empiric antibiotics, but difficulty obtaining cultures must not delay antibiotics. Do not wait for laboratory or imaging results. eviQ recommends IV antibiotics within one hour of presentation when systemic compromise is present.
Apply it
A patient eight days after myelosuppressive chemotherapy has a temperature of 37.2°C, new confusion, and hypotension. Suspect sepsis despite the absence of fever. Activate emergency assessment, establish IV access, assess oxygenation and perfusion, obtain cultures and laboratory studies including lactate, and begin prescribed empiric antibiotics and indicated resuscitation immediately. If a central venous device is present, obtain cultures from its lumens and peripheral blood when feasible without delaying treatment.
Common pitfall: Sepsis can occur without fever, particularly in older patients or those receiving corticosteroids or immunomodulatory therapy. Neither an afebrile reading nor an unconfirmed neutrophil count justifies waiting in a clinically deteriorating patient. Cultures help identify the organism and guide subsequent treatment; culture collection and culture results are not prerequisites for urgent empiric antibiotics.
Infection and Neutropenia during Cancer Treatment | NCI · 123-Neutropenic fever: patient evaluation, risk assessment and immediate management | eviQ
48.Which infusion findings suggest anaphylaxis, and what immediate treatment is required?
Acute bronchospasm, wheezing, hypoxia, or hypotension during an infusion suggests potentially life-threatening systemic hypersensitivity, especially with urticaria. Respiratory or circulatory compromise requires immediate treatment; do not wait for a rash. Stop the infusion, summon emergency assistance, and administer intramuscular epinephrine into the anterolateral thigh under the emergency protocol while supporting airway, breathing, and circulation. The Australian Commission's [Acute Anaphylaxis Clinical Care Standard](https://www.safetyandquality.gov.au/clinical-care-standards/acute-anaphylaxis) supports immediate intramuscular epinephrine as first-line treatment. Antihistamines and corticosteroids must not delay epinephrine and cannot replace its treatment of acute airway and circulatory compromise. The rasburicase prescribing information establishes that anaphylaxis can occur with the first dose and requires immediate, permanent discontinuation after serious hypersensitivity.
Apply it
During a first rasburicase infusion, a patient develops urticaria, wheezing, and hypotension. Stop rasburicase, activate emergency assistance, and administer intramuscular epinephrine immediately according to the anaphylaxis protocol. Provide oxygen, airway support, IV fluid resuscitation as indicated, and repeated reassessment. Document the reaction and the requirement to avoid future rasburicase exposure.
Common pitfall: Treating the visible rash while waiting to see whether an antihistamine works delays essential treatment of bronchospasm and shock. Stopping the infusion and calling for help are necessary but incomplete without prompt epinephrine. Symptom resolution does not justify restarting rasburicase after a serious hypersensitivity reaction.
49.Which back-pain features suggest spinal cord compression?
In a patient with cancer, new or progressive back pain becomes especially concerning with limb weakness, altered sensation, gait change, or bladder or bowel dysfunction. Compression threatens lasting neurological function and requires urgent assessment, MRI, and specialist management. Patients may present before every feature appears, so waiting for paralysis or incontinence delays evaluation. Definitive treatment may involve surgery, radiation, and other prescribed measures. Temporary pain relief does not resolve a persistent neurological deficit or justify routine follow-up.
Apply it
A patient with metastatic cancer reports new back pain and difficulty climbing stairs because the legs feel weak. Escalate urgently for possible cord compression and communicate the onset and progression, even if analgesia lowers the pain score.
Common pitfall: Do not wait for bladder dysfunction or paralysis. Preserved walking and improved pain do not exclude a continuing neurological emergency.
Emergency radiotherapy treatment | Cancer Institute NSW eviQ Education · Spinal cord compression palliative EBRT | eviQ
50.What symptom distribution suggests superior vena cava obstruction?
A mediastinal tumor can compress or obstruct the superior vena cava, impairing venous drainage from the upper body. Head and neck edema together with upper-extremity swelling and dyspnea is a concerning distribution. Cough, hoarseness, dysphagia, headache, or visual disturbance may accompany it. Breathing compromise and cerebral edema can make the condition life-threatening. Recognize the regional pattern and escalate urgently, particularly when respiratory or neurological findings are progressing.
Apply it
A patient with a mediastinal mass develops facial and neck swelling, swollen arms, and increasing breathlessness. Arrange urgent assessment for possible superior vena cava obstruction and communicate the distribution and rate of change.
Common pitfall: Do not treat upper-body swelling as routine generalized fluid retention without assessing its distribution and associated respiratory or neurological symptoms.
Emergency radiotherapy treatment | Cancer Institute NSW eviQ Education
51.What are the immediate actions for suspected vesicant extravasation?
Immediately stop the infusion to prevent further tissue exposure. Leave the access device in place initially for residual-drug aspiration and assessment, and do not flush. Escalate promptly and identify the drug, concentration, approximate amount, site, symptoms, and timing. Compresses and antidotes are agent-specific because drugs differ in tissue injury and whether management aims to limit spread or promote dispersion. Document the affected area and monitor evolving injury using the designated procedure.
Apply it
During a vesicant infusion, a patient reports burning and the site becomes swollen. Stop administration, retain the device for aspiration and assessment, avoid flushing, and activate the extravasation procedure before selecting a compress or antidote.
Common pitfall: Flushing can deliver more vesicant into tissue, and immediate device removal can lose the aspiration route. A universal cold-pack rule is also unsafe.
52.When should a bowel pattern raise concern for obstruction?
Constipation accompanied by worsening abdominal pain, repeated vomiting, distension, or inability to pass gas requires assessment for a serious complication rather than automatic escalation of home bowel treatment. Cancer can obstruct stool passage directly, and chronic constipation can lead to fecal impaction or bowel obstruction. The combined pattern matters more than the number of days without stool. Establish symptom onset, progression, intake, medicines, and prior bowel function while arranging urgent evaluation.
Apply it
A patient with an abdominal tumor develops increasing distension, vomiting, and inability to pass gas. Escalate for urgent assessment before recommending more fiber or additional laxatives, and communicate the known tumor location and symptom progression.
Common pitfall: An opioid prescription does not establish that every bowel problem is uncomplicated opioid constipation. Severe associated symptoms change the pathway even when constipation has occurred before.
Constipation and Cancer | NCI · Nutrition in Cancer Care (PDQ®) - NCI
53.When does diarrhea suggest checkpoint-inhibitor colitis?
Immune checkpoint inhibitors can cause inflammatory injury to the bowel. New diarrhea during or after exposure, especially with abdominal pain, blood, fever, or significant change from baseline, requires prompt assessment for immune-mediated colitis and other causes. It should not automatically be managed as routine chemotherapy-related diarrhea. Establish the treatment history and symptom trajectory because immune adverse effects may occur beyond the infusion day. Early recognition matters because delaying evaluation can allow inflammation and associated complications to worsen.
Apply it
A patient receiving checkpoint therapy reports new frequent diarrhea and abdominal pain and asks which over-the-counter remedy to buy. Arrange prompt oncology assessment and communicate the immune-therapy exposure rather than offering self-treatment as the complete response.
Common pitfall: Do not assume diarrhea is minor because it is a familiar treatment symptom. Checkpoint exposure changes the differential and the urgency of associated warning signs.
54.How does CAR T-cell therapy cause cytokine release syndrome, and how do severity findings guide treatment?
CAR T-cell activation can trigger excessive cytokine release and systemic inflammation, producing cytokine release syndrome (CRS). eviQ applies ASTCT grading principles: fever of at least 38°C, without another attributable cause, is required at onset. Grade 1 has fever without hypotension or hypoxia. Grade 2 involves hypotension without vasopressors and/or hypoxia requiring low-flow nasal oxygen at 6 L/min or less. Grade 3 involves one vasopressor, with or without vasopressin, and/or high-flow nasal oxygen or oxygen by face mask. Grade 4 involves multiple vasopressors, excluding vasopressin, and/or positive-pressure respiratory support. The more severe hypotension or hypoxia determines the grade. After established CRS is treated with antipyretics, tocilizumab, or corticosteroids, continued fever is unnecessary for subsequent grading. Supportive care includes monitoring, fluids, oxygen, and escalation for circulatory or respiratory failure. Assess and treat possible infection concurrently. Tocilizumab targets IL-6 signaling; corticosteroids suppress inflammation. Their timing and use follow the specific cellular-therapy product and institutional protocol, with combined treatment commonly required for severe CRS.
Apply it
After CAR T-cell therapy, a patient has fever, requires 2 L/min nasal oxygen, and needs one vasopressor. The vasopressor requirement makes this grade 3 CRS, although the oxygen requirement alone fits grade 2. Escalate to intensive care, provide hemodynamic and respiratory support, and initiate protocol-directed CRS treatment alongside infection evaluation and empiric antibiotics. If fever resolves after tocilizumab but vasopressor support remains necessary, the absence of fever does not downgrade the ongoing CRS.
Common pitfall: Fever height does not determine CRS grade, and a normal temperature after treatment does not establish recovery. Organ dysfunction requires assessment and treatment but does not independently determine the ASTCT CRS grade. Infection can coexist with CRS: neither antibiotics nor CRS-directed treatment should be delayed while awaiting the infectious workup.
T-cell Transfer Therapy | NCI · 3500-Cytokine release syndrome (CRS) | eviQ
Psychosocial Dimensions of Care10%
55.How can cultural and spiritual preferences shape supportive care?
Supportive cancer care includes physical, emotional, social, and spiritual concerns. Preferences about information, family participation, rituals, and sources of meaning should be elicited from the individual rather than inferred from a cultural or religious label. Ask whom the patient wants involved and what practices matter to them, then incorporate those preferences into feasible care. The discriminating principle is patient-defined meaning and participation. Family wishes can be important without replacing the capable patient’s own voice and expressed choices.
Apply it
A family asks to lead all treatment discussions because of tradition. Privately ask the patient how they want information shared and decisions made, then coordinate communication and any requested spiritual support around those stated preferences.
Common pitfall: Cultural awareness does not justify stereotyping. Do not assume that everyone in a community wants the same information, family involvement, or religious support.
56.How should a nurse respond to altered body image?
Cancer and treatment can change appearance, physical function, and the way a person experiences their body. Distress may concern identity, visibility, confidence, relationships, or loss of control rather than appearance alone. Begin by inviting the patient to explain what the change means and what situations are difficult. Practical resources and counseling can then match the identified need. Reassurance is more useful after understanding the concern; quickly praising survival or minimizing the change can close down an important discussion.
Apply it
A patient avoids social visits after a visible treatment-related change. Ask what feels most difficult about being seen and what support they would welcome, then discuss relevant practical resources or counseling based on that response.
Common pitfall: Saying that appearance should not matter can invalidate distress. Avoid assuming that a cosmetic solution addresses every concern about identity or function.
57.Why should sexuality and intimacy be discussed directly?
Cancer can affect desire, comfort, sexual function, body confidence, and intimacy. Patients may hesitate to raise these concerns, so a respectful invitation can identify needs that otherwise remain hidden. Ask about the patient’s own priorities and relationships without assuming age, gender, orientation, partner status, or sexual practices. Physical and emotional contributors may coexist. The appropriate response begins with assessment and relevant support, rather than assuming that treatment completion automatically restores previous sexual experiences or that intimacy means intercourse alone.
Apply it
A patient says they feel distant from their partner but appears reluctant to elaborate. Offer a private, inclusive discussion of comfort, desire, body confidence, and intimacy, then ask which concern they most want help addressing.
Common pitfall: Do not assume older adults or unpartnered patients have no sexuality concerns. A narrow focus on intercourse can miss the patient’s actual priorities.
58.How does teach-back reveal learning barriers?
Teach-back asks patients to explain key information or demonstrate a task in their own words. It checks how clearly the clinician taught, rather than testing the patient’s intelligence or asking for a yes-or-no assurance. Use plain language, teach a manageable amount, listen for gaps, and explain again differently when needed. Barriers such as distress, hearing problems, language needs, or an overly complex plan can then be addressed. Rechecking understanding completes the loop after clarification.
Apply it
After oral therapy teaching, ask the patient to describe tomorrow’s medication schedule and what they would do after a missed dose. If the explanation differs from the plan, reteach the relevant part and check again.
Common pitfall: Asking whether instructions are understood invites an unreliable yes. Repeating identical jargon more loudly does not resolve a comprehension or language barrier.
59.How should caregiver strain change the support plan?
Caregivers may balance treatment tasks, employment, family responsibilities, and emotional distress while neglecting their own needs. Assessment should ask about sleep, health, workload, confidence with care, and available help. Practical support can include sharing tasks, accepting specific offers of assistance, and arranging relevant services or respite. The goal is a sustainable care plan rather than praise for unlimited endurance. A caregiver’s inability to manage one task signals a need for adjustment, not a failure of commitment.
Apply it
A caregiver reports sleeping poorly and making mistakes while organizing appointments and medicines. Identify the most burdensome tasks, involve the care team in redistributing responsibilities, and explore concrete support rather than simply encouraging greater effort.
Common pitfall: A devoted caregiver can still be overwhelmed. Do not assume willingness proves capacity or that family support is available without asking about actual resources.
60.How can financial toxicity alter treatment adherence?
Cancer-related financial burden can affect medication access, transportation, employment, food security, and emotional well-being. Patients may stretch doses or delay care without volunteering that cost is the reason. Ask directly and without judgment about affordability and practical barriers. The intervention must address the specific problem through appropriate financial, social work, pharmacy, or navigation resources. Better reminders do not solve unaffordable treatment. Recognizing the cause protects both the patient’s dignity and the accuracy of the adherence assessment.
Apply it
A patient repeatedly delays refills despite describing the schedule correctly. Ask whether cost, insurance, or transportation is interfering, then connect the identified barrier with appropriate assistance rather than repeating medication instructions alone.
Common pitfall: Do not interpret cost-related dose stretching as simple forgetfulness. Avoid promising eligibility for assistance or insurance coverage before the relevant program reviews the case.
Financial Toxicity and Cancer Treatment (PDQ®)–Patient Version | NCI
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give the largest study block to Symptom Management and Supportive Care, weighted 25%: link symptom patterns to function, hydration, nutrition, safety, and reassessment.
- For Treatment Modalities, weighted 20%, explain cytotoxic effects, surgical goals, localized tissue destruction, radiation-source status, transplant cell source, immune mechanisms, and oral therapy responsibilities.
- For Oncologic Emergencies, weighted 16%, distinguish metabolic patterns, infection, neurological compression, upper-body venous obstruction, severe infusion reactions, bowel obstruction, extravasation, and immune toxicity. Extend study to every emergency named in the official outline.
- For Oncology Nursing Practice, weighted 15%, separate stage from grade and tumor findings from inherited risk. Connect cancer site and blood-cell function with assessment priorities, and distinguish consent from randomization.
- For Care Continuum, weighted 14%, connect risk reduction, screening, concurrent palliation, advance planning, transitions, and treatment-specific survivorship follow-up.
- For Psychosocial Dimensions of Care, weighted 10%, practise individualized questions about understanding, identity, intimacy, caregiver capacity, spiritual needs, and affordability.
A practical preparation plan
1. Map the complete outline
Use the 2026 OCN outline to mark each topic as familiar, uncertain, or unstudied. Add topics absent from this selective guide, including remaining emergencies, intrathecal and intravesical therapies, additional site-specific cancers, professional practice responsibilities, and psychosocial crisis management.
2. Build mechanism-to-action explanations
For each concept, explain the mechanism, the finding that changes the decision, and the tempting error. Compare related distinctions such as external beam versus implanted-source precautions and tumor profiling versus inherited-risk testing.
3. Practise symptom-pattern assessment
Work through cases using baseline, onset, trajectory, treatment exposure, associated symptoms, and functional impact. State when routine supportive care is reasonable and which cue requires urgent assessment.
4. Use the questions diagnostically
Answer the 20 drills before reading explanations. For every missed or uncertain item, explain why each alternative is less appropriate and identify the missing knowledge or overlooked clinical cue.
5. Rehearse patient teaching
Practise brief explanations of oral dosing, fever reporting, pain rescue plans, radiation safety, and follow-up responsibilities. Use teach-back to verify the patient can describe the intended action in their own words.
6. Complete gaps with official resources
Use ONCC’s reference list and complete outline to expand beyond these samples. Review ONCC’s published sample questions for format familiarity, then revisit weak concepts through spaced recall without treating a practice score as a passing prediction.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Oncology Certified Nurse (OCN®) | ONCC
- Prepare for test | ONCC
- 2026 OCN® Test Content Outline
- 2026 ONCC Certification Test Registration Manual
- Palliative Care in Cancer | NCI
- Follow-Up Medical Care | NCI
- Cancer Screening | NCI
- Biomarker Testing for Cancer Treatment | NCI
- Tumor Grade | NCI
- Are Clinical Trials Safe? | NCI
- Stem Cell Transplants in Cancer Treatment | NCI
- External Beam Radiation Therapy for Cancer | NCI
- Brachytherapy to Treat Cancer | NCI
- Diarrhea and Cancer Treatment | NCI
- Adherence to Oral Agents for Cancer | Oncology Nursing Society
- Cancer Pain (PDQ®)–Health Professional Version | NCI
- Pain and Cancer Treatment | NCI
- Mouth and Throat Problems: Cancer Treatment Side Effects | NCI
- Lymphedema and Cancer | NCI
- Nerve Problems (Peripheral Neuropathy) and Cancer Treatment | NCI
- Fatigue and Cancer | NCI
- Prevention of tumour lysis syndrome | eviQ
- Spinal cord compression palliative EBRT | eviQ
- Emergency radiotherapy treatment | Cancer Institute NSW eviQ Education
- Infection and Neutropenia during Cancer Treatment | NCI
- Tool: Teach-Back | AHRQ
- Financial Toxicity and Cancer Treatment (PDQ®)–Patient Version | NCI
- Definition of performance status | NCI
- How Do Clinical Trials Work? | NCI
- Chemical Hazards Risk Factors | CDC/NIOSH
- Hormone Therapy to Treat Cancer | NCI
- T-cell Transfer Therapy | NCI
- Nausea and Vomiting and Cancer Treatment | NCI
- Weight Changes, Malnutrition, and Cancer | NCI
- Constipation and Cancer | NCI
- Bleeding and Bruising and Cancer Treatment | NCI
- Extravasation management—Clinical procedure | eviQ
- How Cancer Affects Your Self-Image and Sexuality | NCI
- Support for Caregivers of Cancer Patients | NCI
- Cancer Screening Overview - NCI
- Surgery for Cancer - NCI
- OralChemoSafetyatHome.pdf
- Oral Complications (PDQ®) - NCI
- Nutrition in Cancer Care (PDQ®) - NCI
- Elitek.html
- Chemotherapy to Treat Cancer - NCI
- elitek.pdf
- Recommendations | Spinal metastases and metastatic spinal cord compression | Guidance | NICE
- Cardiopulmonary Syndromes (PDQ®) - NCI
- 123-Neutropenic fever: patient evaluation, risk assessment and immediate management | eviQ
- 3500-Cytokine release syndrome (CRS) | eviQ
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.